Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 6/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL809198 | 0.86 | MMP9 (0.45) | PDE2ANR3C1PGR | |
| SCHEMBL809226 | 0.81 | CNR1 (0.50) | CYP1A2CNR1 | |
| SCHEMBL1720295 | 0.76 | MAPK1 (0.45) | PDE2AMAPK1 | |
| SCHEMBL206627 | 0.76 | MAPK1 (0.45) | PDE2AMAPK1 | |
| SCHEMBL1720296 | 0.76 | MAPK1 (0.45) | PDE2AMAPK1 | |
| SCHEMBL808976 | 0.75 | MMP9 (0.47) | PDE2ACYP1A2 | |
| SCHEMBL4344623 | 0.75 | MMP9 (0.47) | PDE2ACYP1A2 | |
| SCHEMBL18247937 | 0.75 | PDE2A (0.53) | PDE2A | |
| SCHEMBL20266799 | 0.75 | PDE2A (0.53) | PDE2A | |
| SCHEMBL4536126 | 0.74 | MAPK1 (0.43) | PDK1PDK2PDK3PDK4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1593674-B1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7683215-B2 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-23 | — | — | US | disclosed |
| US-7671213-B2 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20080076941-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ITAGAKI MAKOTO | 2008-03-27 | — | — | US | disclosed |
| US-20080076931-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ITAGAKI MAKOTO | 2008-03-27 | — | — | US | disclosed |
| CN-101125833-A | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL CO (JP) | 2008-02-20 | — | — | CN | disclosed |
| US-7288674-B2 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-10-30 | — | — | US | disclosed |
| US-20060149077-A1 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| CN-1771236-A | Optically active bisoxazoline compound, process for producing the same, and use thereof | SUMITOMO CHEMICAL CO (JP) | 2006-05-10 | — | — | CN | disclosed |
| EP-1593674-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149077-A1 | Optically active bisoxazoline compounds, process for production of the same and use thereof | ACSL3, ADSL, SQLE | PDE2A 1693/4885CYP2A6 206/4885CYP1A2 25/4885 |
| US-20080076941-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ACSL3, ADSL, SQLE | PDE2A 1693/4885CYP2A6 206/4885CYP1A2 25/4885 |
| US-20080076931-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ACSL3, ADSL, SQLE | PDE2A 1693/4885CYP2A6 206/4885CYP1A2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.